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ABSTRACT 
Background Heterozygous mutations in COL10A1 underlie metaphyseal chondrodysplasia, 
Schmid type (MCDS), an autosomal dominant skeletal dysplasia. 
Objective To identify the causative variant in a large consanguineous Pakistani family with 
severe skeletal dysplasia and marked lower-limb deformity.  
Methods Whole-Exome sequencing was completed followed by Sanger sequencing to verify 
segregation of the identified variants. In silico variant pathogenicity predictions and amino acid 
conservation analyses were performed. 
Results A homozygous c.133 C>T (p.Pro45Ser) variant was identified in COL10A1 in all six 
severely affected individuals (adult heights 119 cm-130 cm, mean~-6.33 SD). The individuals 
heterozygous for the variant had mild phenotype of short stature (adult heights 140 cm-162 cm, 
mean~-2.15 SD) but no apparent skeletal deformities. The variant was predicted to be pathogenic 
by in silico prediction tools and was absent from public databases and hundred control 
chromosomes. Pro45 is conserved in orthologues and is located in the non-collagenous 2 domain 
of COL10A1, variants of which have never been associated with skeletal dysplasia.  
Conclusions This first report of individuals with a homozygous variant in COL10A1 defines a 
new type of autosomal recessive skeletal dysplasia. The observations in COL10A1 variant 
carriers suggest a phenotypic overlap between the mildest forms of MCDS and idiopathic short 
stature. 
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 INTRODUCTION  
Metaphyseal chondrodysplasia, Schmid type (MCDS; OMIM 156500) is an autosomal dominant 
disorder. It is characterized by short stature, long bone deformities such as genua vara and coxa 
vara, and radiographic signs of methaphyseal dysplasia. Fifty heterozygous mutations in 
COL10A1 encoding type X collagen have been reported to cause MCDS (Human Gene Mutation 
Database; http://www.hgmd.cf.ac.uk/ac, accessed in June 2017). Type X collagen is a 
homotrimer non-fibrillar collagen, composed of three alpha-1(X) chains of 680 amino acids. It is 
present in the extracellular matrix and is exclusively produced by the hypertrophic chondrocytes 
during the endochondral ossification.
1
 The protein plays a role in distribution of proteoglycans 
and vesicles in bone matrix. COL10A1 is comprised of a signal peptide (amino acids 1-18) at the 
N-terminal followed by a non-collagenous 2 (NC2) region (19-56), a triple-helical region (57-
519) and a non-collagenous 1 (NC1) region (520-680) at the C-terminal.
1
 
 
All except three mutations
2 3
 known to cause MCDS affect the NC1 region. Haploinsufficiency is 
one of the proposed mechanisms for the disorder since a 50% reduction of COL10A1 is observed 
in bone cartilage of MCDS patients who are heterozygous for some nonsense and frameshift 
mutations.
4 5
 Dominant-negative effects of COL10A1 nonsense and missense variants have also 
been shown to be responsible for causing the disorder.
6
 The NC1 region contains motifs required 
for trimerization of COL10A1 and a loss of NC1 leads to improper trimerization of collagen,
7
 
resulting in accumulation of these misfolded proteins in the cells. This leads to endoplasmic 
stress and apoptosis in hypertrophic chondrocytes during endochondral ossification.
8 9
 However, 
mutations that result in a change of amino acid at the exterior of NC1 region (p.Asp617Lys and 
p.Gly618Val) allow trimerization but hinder supramolecular assembly and interaction of  
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COL10A1 with endoplasmic reticulum and proteins in extracellular matrix.
10 11
 In addition, 
mutations of residues which introduce a charge deep inside the hydrophobic NC1 domain affect 
the trimerization process and produce unstable COL10A1 which is degraded in the endoplasmic 
reticulum
8
 resulting in haploinsufficiency. Some NC1 missense variants, for example 
(p.Tyr598Asp) have been demonstrated to give rise to formation of abnormal disulfide bonds by 
exposing sulfhydryl groups of cysteine which are normally buried inside protein in the normal 
configuration.
8
  
 
To date, all patients reported with pathogenic variants in COL10A1 have been heterozygous. In 
the present study, we describe a large consanguineous family with a novel missense variant of 
COL10A1 leading to a pronounced phenotype with severe short stature and lower-limb 
deformities in homozygous individuals while family members harbouring a heterozygous variant 
were only mildly affected. This is the first disease-causing variant in COL10A1 located in the 
NC2 domain of the protein. Further, to the best of our knowledge, this is the first report of 
individuals with a homozygous variant in COL10A1.  
 
MATERIALS AND METHODS 
 Patients  
The study was approved by the Institutional Review Board at the School of Biological Sciences, 
University of the Punjab, Lahore, Pakistan. Family NAD-02 (figure 1A) was recruited to the 
study after obtaining written informed consents from the participants or their parents. A detailed 
history about the onset and progression of growth failure and deformities was obtained. Family 
history was recorded and photographs were taken. Ages and heights of all family members were 
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recorded and standard deviation scores for heights were calculated using WHO population-based 
reference values. Medical radiographs could not be obtained as all family members refused the 
testing. Peripheral blood samples were drawn from the participants. DNA was isolated using a 
standard protocol.
12
  
 
Molecular Analysis 
Whole-exome sequencing (WES) was performed for one severely affected individual IV:15, 
using Agilent V4 enrichment kit (Agilent Technologies, Santa Clara, CA). Paired-end reads were 
obtained at 50× coverage on an Illumina Hi-Seq 2000 sequencer (Otogenetics, Norcross, GA). 
Reads were mapped to UCSC hg19 reference human genome (http://genome.ucsc.edu/). The web 
based program wANNOVAR was used for further annotating variants. All heterozygous variants 
and variants in dbSNP database, Exome Aggregation Consortium (ExAC), 1000 Genomes and in 
6500 exon sequence project with minor allele frequency (MAF) greater than 0.0099 were 
removed. Exonic and splice site variants were considered. Homozygous chromosomal intervals 
in the exome data were identified using Agilevariant mapper and intronic and synonymous 
variants located in these regions were also scrutinized. The disease causing potential of sorted 
variants was checked by using online prediction programs which included Polyphen2, Mutation 
taster, Mutation Assessor and fathmm. ClustalO was used for generating protein alignment of 
COL10A1 orthologous sequences retrieved from UCSC genome browser. Primers for the 
amplification of genomic regions containing the selected variants were designed using Primer3. 
The segregation of each variant with the phenotype was checked after PCR amplification of the 
specific product followed by Sanger sequencing with Big Dye Terminator V3.1 cycle 
Sequencing kit (Applied Biosystems). 
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RESULTS 
Clinical Features 
Family NAD-02 had eight severely affected individuals born in four consanguineous marriages 
(figure 1A). Six affected individuals participated in the study. All severely affected individuals 
had severe disproportionate short stature with short limbs and significant lower limb varus or 
valgus deformity but normal facial features (Table 1). Their growth was reported to be normal 
until the age of 6 years. However, no longitudinal height data were available. The adult heights 
ranged from 114 cm to 130 cm (Table 1). Lower limb deformities progressed with age in all, 
with older individuals complaining of joint pain in knees. None of the patients had significant 
scoliosis. Bowing of legs was visible but hands and feet were normal. One individual (IV:2) 
homozygous for the variant had genu valgum while all other severely affected individuals had 
genu varus. Apart from the skeletal findings, no other clinical signs, including intellectual 
disability, infections, respiratory problems or hearing deficits were present in any of the affected 
individuals. Family members who were obligate carriers and those who were subsequently found 
to be heterozygous for the disease-causing variant were apparently normal but had mild short 
statures (adult heights from 140 cm to 162 cm) (Table 1). They did not complain of joint pain or 
other heath related issues. None of these individuals considered themselves as affected. 
 
Molecular Findings 
Analysis of the whole exome sequencing data revealed a novel homozygous missense mutation 
in exon 2 of COL10A1, c.133 C>T (p.Pro45Ser) which fully co-segregated with the disease 
phenotype in the family, with the six severely affected individuals being homozygous for the 
variant (figures 1A, 1B, Supplementary Table 1). Analysis of data for individual 1V:15 indicated 
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that all coding exons located in the homozygous chromosome 6 interval (114-130 MB, according 
to GRCh37/hg19, data not shown), in which COL10A1 is located, were fully covered by exome 
sequencing. No other potential pathogenic variant was identified in the exome data within this 
region of homozygosity on chromosome 6 and none of the other variants on different 
chromosomal intervals segregated with the phenotype (Supplementary Table 1). 
The COL10A1, c.133 C>T (p.Pro45Ser) mutation was absent from public databases including 
gnomAD (http://gnomad.broadinstitute.org/) as well as in ethnically matched 100 control 
chromosomes. The variant was predicted to be pathogenic or damaging by all four prediction 
programs and also had a high Combined Annotation Dependent Depletion (CADD) score of 
14.55 (Supplementary Table 1). The Pro45 amino acid is absolutely conserved in COL10A1 
orthologues (figure 1C).  
 
DISCUSSION 
Variants of COL10A1 have been shown to cause metaphyseal chondrodysplasia, Schmid type in 
humans and chondrodysplasia in mice. Both haploinsufficiency and dominant-negative gain of 
function are proposed mechanisms for MCDS. Here we describe a new form of skeletal 
dysplasia caused by biallelic mutations in COL10A1 resulting in a skeletal phenotype which is 
reminiscent of MCDS caused by heterozygous COL10A1 variants but with more severe 
symptoms. Interestingly, the carriers of (p.Pro45Ser) variant had mild short statures but no other 
phenotypic manifestations. One explanation for this variant causing the severe manifestations of 
the disorder only in the homozygous form could be due to the unusual site of the mutation 
(figure 1D). The variant identified in the present family is located in the NC2 region of 
COL10A1, in which no pathogenic variants have been identified previously. All reported 
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dominantly inherited mutations in MCDS patients are located in the NC1 region of COL10A1 
except for three variants.
2 3
 These COL10A1 heterozygous variants affect the signal peptide 
(p.Gly18Arg), (p.Gly18Glu) or the triple helical domain (p.Gly288Arg) of COL10A1 (figure 1D, 
Supplementary Table 2). The three variants are associated with late onset and mild forms of 
MCDS.
2 3
  
 
All except one (p.Val677Glu) of the pathogenic variants of NC1 region of COL10A1 (figure 1D 
and Supplementary Table 2) result in the development of a severe form of the disease. The NC1 
domain has been shown to play a vital role in the trimerization of collagen X.
7
 Moreover, it has 
been proposed that the NC1 region interacts with other proteins and any alteration in the NC1 
region may also lead to accumulation of its interacting proteins inside cells, adding to pathology 
of disease.
13
  
 
Homozygous Col10a1
-/- 
 null mutant mice exhibit late onset extremely mild abnormalities.
14
 
These mutant mice develop unilateral coxa vara on ageing. The observed difference in the 
severity of phenotype between mice and humans was proposed to be due to the difference in the 
weight borne by growth plates in both species.
14
 However, transgenic wild-type mice transfected 
with mutant COL10A1 develop a severe phenotype with genu valgum, coxa vara and short 
stature similar to that found in human MCDS patients heterozygous for these mutations.
15 16
 The 
severity of the disease in these mice is gene dosage dependent with homozygous mutant mice 
being more severely affected than their heterozygous littermates.
15 16
 We speculate that the 
(p.Pro45Ser) variant causes the disease in a dosage dependent manner similar to that seen for 
transgenic mice with COL10A1 mutations.  
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The lack of radiographs for the participants in our study hinders an unequivocal phenotypic 
diagnosis for both individuals heterozygous and homozygous for the variant. Nevertheless, the 
variant (p.Pro45Ser) in the present family results in a later onset (at around 6 years of age) of an 
extremely severe disorder only in individuals carrying the homozygous variant. The usual age of 
onset in dominantly inherited MCDS is between 1 to 4 years.
17
 It has been speculated that late 
onset of the disease associates with mutations leading to complete nonsense-mediated RNA 
decay of the mutated transcripts, while the more common early onset forms are caused by 
mutations with incomplete nonsense-mediated decay and dominant-negative impairment of 
protein folding, endoplasmic reticulum stress response and altered hypertrophic chondrocyte 
differentiation.
18
  
 
The heterozygous carriers of the (p.Pro45Ser) variant had short heights, but did not exhibit 
apparent skeletal anomalies or other associated clinical features observed in those with 
dominantly inherited MCDS or in the homozygous affected individuals in their own family. 
Although we cannot exclude the possibility of a skeletal phenotype detectable by radiography in 
heterozygous individuals with (p.Pro45Ser) variant, the absence of visible skeletal defects in 
these individuals suggest variants in COL10A1 are attractive candidates for idiopathic short 
stature. The phenotypic variability among patients harbouring different COL10A1 mutations also 
indicates complexity in the disease mechanism.  
 
The pathogenic mechanism through which the missense variant (p.Pro45Ser) leads to severe 
short stature in our patients remains to be elucidated. The crystal structure for NC-2 domain of 
COL10A1 is not available, thus precluding prediction of the potential effects of the variant on 
10 
 
the protein. However, proline has unusual properties since it is a cyclic -imino acid rather than 
an -amino acid. Unlike other amino acids, the -carbon atom is part of a cyclic pyrrolidine ring, 
which is thus introduced into the polypeptide backbone  on incorporation of proline.
19
 Moreover, 
there is no hydrogen bond donor in the amide bond.   Incorporation of proline produces bends 
and its inclusion can serve as a helix breaker in the polypeptides. Additionally, though usually 
found in the cis state, it has been proposed that proline residues may act as molecular switches in 
mature proteins by transitioning between the cis and trans states.
20
 The substitution of serine 
residue at position 45 may affect some of these unique properties conferred by proline. In 
addition, serine is an amino acid with a hydrogen bond donor. This may affect the bonding of 
COL10A1 or lead to its aberrant interactions with other proteins.  Determination of the crystal 
structure of NC-2 domain is required to elucidate the precise mechanism of (p.Pro45Ser) 
variant’s effect. The knowledge gained from in vitro and in vivo analyses of COL10A1 variants 
will lead to better understanding of its function in health and disease.  
 
Web resources 
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Exome Variant Server (http://evs.gs.washington.edu/EVS/) 
Fathmm (http://fathmm.biocompute.org.uk/inherited.html) 
gnomAD (http://gnomad.broadinstitute.org/) 
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Human gene mutation database (http://www.hgmd.cf.ac.uk/) 
Mutation taster (http://www.mutationtaster.org/) 
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Online Mendelian Inheritance in Man, OMIM, (http://www.omim.org) 
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Legends 
Figure 1: Family NAD-2 with the c.133 C>T (p.Pro45Ser) variant, sequence conservation 
and schematic representation of COL10A1. 
 
(A) Pedigree of family NAD-2. Double lines indicate consanguineous marriages, filled symbols 
represent homozygous affected individuals and symbols with dots denote the heterozygous 
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carriers of the variant. Genotypes for COL10A1 variant c.133 C>T are provided for all 
participants below their symbols.  
 
(B) Partial chromatograms of DNA sequence of COL10A1. Arrows indicate the point of 
mutation. 
 
 
 
 
(C) Clustal Omega sequence alignment of COL10A1 from diverse vertebrate species showing 
conservation of Proline in all orthologues. The conserved amino acids are highlighted in grey. 
The asterisk signs below the alignment indicate evolutionary conserved amino acids, a colon 
indicates highly conserved amino acids, and the periods symbolize less conserved amino acid 
changes. 
 
 
 
 
 
 
 
 
 
(D) Schematic representation of COL10A1. The amino acid numbers corresponding to each 
domain are shown by integers. Vertical lines with integers show all variants of COL10A1 in the 
signal peptide, NC2 and the triple helical region as well as selected changes from 47 variants 
affecting NC1. The newly identified variant is boxed. S, signal peptide; NC2, non-collagenous 
domain 2; Helix, triple helical domain and NC1, non-collagenous domain 1. The amino acids for 
start and ends of domains are: 1-18 S, 19-56 NC2, 57-519 Helix and 520-680 NC1. 
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Table 1: Genotype and phenotype of individuals in family NAD-02 
 
Name Sex  Age (years) Height (cm) SD Deformity  Zygosity  Gait  
III:1 F 58 145 -2.8 No  Heterozygous  Normal  
III:2 F 56 140 -3.5 No  Heterozygous  Normal  
III:3 M 60 160 -2.3 No  Heterozygous  Normal  
III:4 M 58 162 -2.0 No  Heterozygous  Normal  
III:5 F 58 147 -2.5 No  Heterozygous  Normal  
III:6 M 62 162 -2.0 No  Heterozygous  Normal  
IV:1 M 23 130 -6.4 Genu varum Homozygous  Waddling  
IV:2 M 18 130 -6.1 Genu valgum Homozygous Waddling 
IV:3 M 29 168 -1.2 No  Wild  type Normal  
IV:4 M 18 160 -2.2 No  Heterozygous  Normal  
IV:6 F 21 114 -7.5 Genu varum Homozygous Waddling  
IV:11 F 16 119 -6.8 Genu varum Homozygous Waddling  
IV:15 M 21 130 -6.4 Genu varum Homozygous Waddling  
IV:16 M 14 122 -4.8 Genu varum Homozygous Waddling  
IV:17 M 28 168 -1.2 No  Wild type Normal  
IV:4 M 18 150 -3.7 No  Heterozygous  Normal  
 SD: standard deviation, cm: centimeter  
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